Company Profile

Yangling Jinhai Biotechnology Co., Ltd. (hereinafter referred to as “Yangling Jinhai”) is approved by the Ministry of Agriculture, and is supported by Shanghai Haili Biotechnology Co., Ltd. (hereinafter referred to as “Haili Bio”) and Argentina Biogénesis Bagó SA (hereinafter referred to as “BAGO Company”. ") The joint venture company that uses the current international advanced suspension culture process and concentration and purification technology to produce highly purified foot-and-mouth disease inactivated vaccine. Jinhai Bio has a registered capital of RMB 100 million, with the Chinese holding 60% and the foreign holding 40%. The registered address of Jinhai Bio is No. 31, Donghuan North Road, Yangling Agricultural High-tech Industry Demonstration Zone, Shaanxi.

Haili Bio, the controlling shareholder, is a leading professional veterinary biological product manufacturer integrating R&D, production, sales and service. It is the production base of animal major epidemic prevention and control biological products established by the Ministry of Agriculture in Shanghai. The technology enterprise, the key leading enterprise of agricultural industrialization in Shanghai, and the cultivation of small and medium-sized enterprises in Shanghai, the vaccine products won the title of “Shanghai Famous Brand”. At the same time, Haili Bio is also a training base for biotechnology professionals at Shanghai Agriculture and Forestry Vocational and Technical College.

Founded in 1938, the foreign shareholder BAGO has a history of more than 70 years of production and management of animal drugs (veterinary drugs). It is recognized as a leading manufacturer in Argentina and even in the world in the field of foot-and-mouth disease vaccines, and has the largest market share in the world. BAGO is the only manufacturer in the world to supply US and Canadian foot and mouth disease vaccines in emergencies.

Yangling Jinhai relies on the capital advantages, management advantages and technological advantages of shareholders to introduce the most advanced foot-and-mouth disease vaccine manufacturing technology into China. Yangling Jinhai invested RMB 500 million to implement the foot-and-mouth disease vaccine production base construction project started construction in 2014; in 2016, it passed the veterinary drug GMP static and dynamic certification and obtained the production license; in April 2017, the veterinary drug product obtained from pig double O seedlings was obtained. The approval number was obtained, and in February 2018, the approval number of the veterinary drug product of the second price of the cow was obtained. After the project is put into production, it will realize an annual production capacity of 400 million doses of foot-and-mouth disease vaccine, which will play a major role in the prevention of foot-and-mouth disease in China.